RxDoctor Payments Data

Linda Chan, MD

Radiation Oncology · Laguna Hills, CANPI 1083844427

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Novocure Inc. at 39.5% of the total. Reporting peaked in 2021 at $198 and has fallen 63.5% since, to $72 in 2025.

$598in general payments, 2019–2025

Across 19 payments — averaging $31.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novocure Inc.$236
  • Reflexion Medical, Inc.$75
  • Siemens Medical Solutions USA, Inc.$73
  • Bioprotect Medical, Inc.$43
  • Palette Life Sciences, Inc.$33
  • GE HealthCare$28
  • plus $110 from 5 others
$40,615in research payments, 2019–2025

Across 18 payments — averaging $2256.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novocure Inc.$40K
  • GT Medical Technologies, Inc$814

What the payments were for

  • Food & beverage$598100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$598 in reported general payments places this provider in the 55th percentile of 627 radiation oncology providers in California.

See all radiation oncology providers in California

Medicare billing

Part B allowed, 2024
$49,668
Medicare patients
92
Services billed
505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tamsulosin Hcl34$781

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →